Picture of Anika Therapeutics logo

ANIK Anika Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapHigh Flyer

Anika Therapeutics Inc expected to post earnings of 5 cents a share - Earnings Preview

* Anika Therapeutics Inc  ANIK.OQ   ANIK.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 8
for the period ending June 30 2024
    * The Bedford Massachusetts-based  company is expected to
report a
5.0% decrease in revenue to $42.099 million from $44.3 million a
year ago, according to the mean estimate from 3 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Anika Therapeutics Inc
is for
earnings of 5 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Anika
Therapeutics Inc is $32.00​, above​ its last closing price
of $26.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.21       -0.19      -0.31     Missed  -66.1
 Dec. 31 2024              -0.26      -4.30     Missed  -1,532
                                                        .9
 Sep. 30 2023  -0.38       -0.37      -0.45     Missed  -20.5​
 Jun. 30 2023  -0.27       -0.27      -0.19     Beat    29.6
 ​​Mar.        -0.33       -0.30      -0.47     Missed  -56.7
 31 2023                                                
 Dec. 31 2022  -0.25       -0.24      -0.34     Missed  -41.7​
 Sep. 30 2022  -0.25       -0.25      -0.15     Beat    40
 Jun. 30 2022  -0.21       -0.23      -0.20     Beat    11.8
 This summary was machine generated August 7 at 02:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Anika Therapeutics

See all news